A Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long-acting rhGH-HMC001 Conjugate in Treatment of Subjects Suffering From Adult Growth Hormone Deficiency (AGHD)
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2016
Price : $35 *
At a glance
- Drugs Efpegsomatropin (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 31 Aug 2018 Biomarkers information updated
- 20 May 2015 Status changed from active, no longer recruiting to completed.
- 13 Mar 2015 According to a Hanmi Pharmaceuticals media release, interim results were presented at the Endocrine Society conference (ENDO) 2015.